CN101555519A - Gene chip and application thereof - Google Patents
Gene chip and application thereof Download PDFInfo
- Publication number
- CN101555519A CN101555519A CNA2008100358406A CN200810035840A CN101555519A CN 101555519 A CN101555519 A CN 101555519A CN A2008100358406 A CNA2008100358406 A CN A2008100358406A CN 200810035840 A CN200810035840 A CN 200810035840A CN 101555519 A CN101555519 A CN 101555519A
- Authority
- CN
- China
- Prior art keywords
- seq
- ribonucleic acid
- homo sapiens
- probe
- liver cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a gene chip and an application thereof. The invention discloses a micro ribonucleic acid specifically expressed in liver cancer tissues and an application of the same. The gene chip is a chip which contains a probe specific to the micro ribonucleic acid and can be used for preparing reagent or a kit for differentiating liver cancer tissues, tissues adjacent to carcinoma and/or normal tissues, for preparing reagent or kit for testing liver cancer and for the auxiliary diagnosis of liver cancer.
Description
Technical field
The present invention relates to biological technical field, relate in particular to a kind of gene chip and related application thereof that contains specifically at the probe of micro ribonucleic acid.
Background technology
Liver cancer is one of the kinds of tumor in South East Asia and South Africa, and its mortality ratio is also very high.Human diseases much is because some genetic expressions are disorderly or out of control caused.Micro ribonucleic acid (little RNA, microRNA, miRNA) be the strand microRNA of the not coded protein of the about 21-25nt of a class length, extensively be present in the eukaryote, being attached to by nucleic acid array complementation and regulating said target mrna translation or degraded said target mrna on the specific said target mrna, is a kind of molecule that plays the negative regulation effect.Studies show that at present many miRNA have participated in physiological processs such as organism growth, differentiation, growth, immunne response, and its expression and functional disorder may cause tumour that multiple pathological phenomenons such as leukemia and virus infection take place.
Although having report to show in the processes such as miRNA may grow organism, tumour generation at present plays a significant role.This area still presses for the miRNAs express spectra of understanding in liver cancer.
Summary of the invention
The present invention aims to provide a kind of chip that contains specifically at the probe of micro ribonucleic acid, and described micro ribonucleic acid is peculiar in the liver cancer tissue.
Another object of the present invention provides a kind of test kit, comprises above-mentioned chip in the described test kit.
A further object of the present invention provides the purposes of said chip, and described purposes is the test kit that liver cancer tissue, cancer beside organism and/or healthy tissues are differentiated in preparation.
The 4th purpose of the present invention provides a kind of purposes of micro ribonucleic acid.
The 5th purpose of the present invention provides the method for the medium and small ribonucleotide of a kind of external non-diagnostic assays nucleic acid samples.
The 6th purpose of the present invention provides a kind of method that detects liver cancer.
The 7th purpose of the present invention provides the method for a kind of screening potential material relevant with the small nut sugar nucleotide express spectra of liver cancer.
In a first aspect of the present invention, a kind of chip is provided, it contains specifically at the probe of micro ribonucleic acid, and the sequence of described micro ribonucleic acid is shown in SEQ ID NO:1-10.
In another preference, described chip also contains specifically the probe at the micro ribonucleic acid of one or more sequences shown in SEQ ID NO:11-41; More preferably, described chip also contains specifically the probe at the micro ribonucleic acid of one or more sequences shown in SEQ ID NO:42-84.
In a second aspect of the present invention, a kind of test kit is provided, described test kit comprises:
One container;
Be arranged in described container specifically at the probe of micro ribonucleic acid, the sequence of described micro ribonucleic acid is shown in SEQ ID NO:1-10; And
Specification sheets;
And every kind of probe links to each other with detectable mark, and the detected mark that links to each other on the different probe is also different; Preferably, described mark is fluorescent microsphere, indole cyanine dyes.
In another preference, also contain positive reference substance in the described test kit, described positive reference substance is to contain specifically at the probe of micro ribonucleic acid, the sequence of described micro ribonucleic acid is shown in SEQ ID NO:1-10; Every kind of probe links to each other with detectable mark, and described mark is CY3.
In another preference, also contain specifically probe in the described test kit at the micro ribonucleic acid of one or more sequences shown in SEQ IDNO:11-41; Preferably, also contain specifically probe in the described test kit at the micro ribonucleic acid of one or more sequences shown in SEQ ID NO:42-84.
In a third aspect of the present invention, a kind of test kit that is used to detect liver cancer is provided, described test kit contains as above-mentioned chip and specification sheets.
In a fourth aspect of the present invention, a kind of purposes as above-mentioned chip is provided, described chip is used to prepare the test kit of differentiating liver cancer tissue, cancer beside organism and/or healthy tissues.
In a fifth aspect of the present invention, a kind of purposes of micro ribonucleic acid is provided, wherein said micro ribonucleic acid comprises the oligonucleotide of sequence shown in SEQ ID NO:1-10, and described micro ribonucleic acid is used for reagent or the test kit that liver cancer tissue, cancer beside organism and/or healthy tissues are differentiated in preparation (a); Or (b) detect the reagent or the test kit of liver cancer; Preferably described reagent is specifically at the probe of described micro ribonucleic acid.
In a sixth aspect of the present invention, the method for the medium and small ribonucleotide of a kind of external non-diagnostic assays nucleic acid samples is provided, described method comprises step:
(i) nucleic acid samples is contacted with the probe at micro ribonucleic acid specifically, the sequence of described micro ribonucleic acid is shown in SEQ ID NO:1-10; With
(ii) per sample with the hybridisation events of the probe of micro ribonucleic acid, obtain the express spectra of described micro ribonucleic acid.
Preferably, described probe is positioned on the chip; More preferably, described nucleic acid samples is an extracting nucleic acid.
In a seventh aspect of the present invention, a kind of method that detects liver cancer is provided, described method comprises step:
(i) system to be checked is contacted with the probe that contains specifically at micro ribonucleic acid, the sequence of described micro ribonucleic acid is shown in SEQ ID NO:1-10;
(ii) observe the hybridisation events of system to be checked and described probe, wherein, if described system to be checked can with probe hybridization, show that then there is the possibility of liver cancer in this system to be checked;
Described system to be checked is selected tissue, cell system or extractive nucleic acid.
In a eighth aspect of the present invention, a kind of method of screening of candidate substances is provided, described method comprises step:
(a) will wait to screen material contacts with the liver cancer cell culture of experimental group, detect micro ribonucleic acid in the described liver cancer cell then, the sequence of wherein said micro ribonucleic acid is shown in SEQ ID NO:1-10, thus the express spectra of little ribonucleotide described in the acquisition experimental group liver cancer cell;
(b) express spectra with little ribonucleotide described in the express spectra of little ribonucleotide described in the experimental group liver cancer cell and blank group express spectra and the normal liver cell compares, and described blank group express spectra is a liver cancer cell culture of waiting to screen material from not adding;
Wherein, if concordance rate＜70% of experimental group express spectra and blank group express spectra illustrates that this material to be screened is the potential material relevant with the small nut sugar nucleotide express spectra of liver cancer, can be used as the basis of further screening; Preferably, concordance rate＜50%, more preferably, concordance rate＜20%.
In view of the above, the invention provides the miRNAs express spectra in liver cancer, and finished foregoing invention with this.
Description of drawings
Fig. 1 has shown the express spectra of the miRNA of differential expression in liver cancer, cancer side and normal liver tissue.
Fig. 2 has shown the result of real-time RT-PCR proofing chip; Wherein
A1 is respectively the result of 8 mi RNA to a8; The sample that the X-axis representative is different, Y-axis are represented the cancer expression level other relative with cancer, and data serve as with reference to having done the multiple conversion with the other expression values of cancer all;
On behalf of 8 miRNAs, the chip of the mi RNAs that the X-axis representative of b is different and the result that real-time RT-PCR detects, Y-axis detect the other ratio of cancer/cancer of gained expression values with chip and real-time RT-PCR.
Embodiment
The contriver has been surprised to find some miRNA through extensive and deep research, and all there were significant differences in the expression of these miRNA (sequence shown in SEQ IDNO:1-10) between liver cancer, cancer side and the per two kinds of tissues of normal liver tissue:
Micro ribonucleic acid (has-miR-101) with nucleotide sequence shown in the SEQ ID NO:1,
Micro ribonucleic acid (has-miR-148a) with nucleotide sequence shown in the SEQ ID NO:2,
Micro ribonucleic acid (has-miR-181a) with nucleotide sequence shown in the SEQ ID NO:3,
Micro ribonucleic acid (has-miR-214) with nucleotide sequence shown in the SEQ ID NO:4,
Micro ribonucleic acid (has-miR-221) with nucleotide sequence shown in the SEQ ID NO:5,
Micro ribonucleic acid (has-miR-222) with nucleotide sequence shown in the SEQ ID NO:6,
Micro ribonucleic acid (has-miR-25) with nucleotide sequence shown in the SEQ ID NO:7,
Micro ribonucleic acid (has-miR-29c) with nucleotide sequence shown in the SEQ ID NO:8,
Have nucleotide sequence shown in the SEQ ID NO:9 micro ribonucleic acid (has-miR-34a) and
Micro ribonucleic acid (has-miR-424) with nucleotide sequence shown in the SEQ ID NO:10.
Based on above-mentioned new discovery of the present invention, the contriver has finished a series of invention, such as but not limited to:
1, obtain a kind of gene chip (microarray chip), containing on the chip can be specifically with above-mentioned miRNA bonded probe;
2, a kind of reagent or test kit that is used to differentiate liver cancer tissue, cancer beside organism and/or healthy tissues of preparation;
3, the reagent or the test kit of a kind of Preliminary detection liver cancer of preparation;
4, detecting can be with the method for above-mentioned miRNA specificity bonded material;
5, be used to carry out preliminary somatotype, differential diagnosis and/or the susceptibility analysis of liver cancer;
6, the ill risk that is used for the relevant crowd's liver cancer of entry evaluation, early monitoring, early prevention;
7, be used for the relevant crowd's of entry evaluation cancer treatment drug, curative effect of medication, prognosis, and select suitable methods of treatment.
The present invention includes the expression level that can be used for detecting miRNA, so differentiate liver cancer tissue, cancer beside organism and/or healthy tissues test kit, can comprise specifically probe in the described test kit at miRNA.Preferably, described probe carries detectable signal.Described probe can be fixed on microarray (microarray) or the gene chip.
The invention still further relates to quantitative and qualitative detection miRNA level, thereby judge the generation of liver cancer or the diagnostic testing process of development.These tests are known in the art, for example include, but is not limited to: real-time fluorescence quantitative PCR, cluster analysis, distribution free Mann-Whitney check, Spearman correlation analysis etc.
A kind of method that whether has described miRNA and amount thereof in tissue to be measured or the sample that detects is to utilize real-time fluorescence quantitative PCR to detect, it comprises: the specific probe (described probe preferably carries detectable signal) for preparing each miRNA, the Auele Specific Primer for preparing each miRNA, carry out PCR, judge the level of described miRNA then by the power that detects the detectable signal after PCR finishes.As optimal way of the present invention,, be that the basis is detected promptly with the TaqMan fluorescent probe based on the TaqMan fluorescence technique.The TaqMan fluorescent probe is a kind of oligonucleotide, and its two ends are a fluorescent emission group of mark (as detectable signal) and a fluorescent quenching group respectively.When probe was complete, fluorescent emission group fluorescent signal emitted was absorbed by quenching group; During pcr amplification, 5 '-3 ' 5 prime excision enzyme activity of Taq enzyme is cut degraded with the probe enzyme, the fluorescent emission group is separated with the fluorescent quenching group, thereby can receive fluorescent signal by fluorescence detecting system, it is DNA chain of every amplification, just have fluorescence molecule to form, promptly the accumulative total of fluorescent signal and PCR product form fully synchronously, thereby realize qualitative and quantitative.
Specific primer of described micro ribonucleic acid and/or probe are also contained in the present invention, are used for test sample and whether have described micro ribonucleic acid and amount thereof, thereby be used to judge whether the experimenter suffers from liver cancer or ill risk.Described probe can be fixed on microarray (microarray) or the gene chip, is used for analyzing differential expression analysis and the gene diagnosis of tissue or sample miRNA.
Chip provided by the invention contains specifically at the probe of miRNA, and described miRNA is sequence shown in SEQ ID NO:1-10; Preferably, described chip also contains specifically the probe at the miRNA of sequence shown in SEQ ID NO:11-41; More preferably, described chip also contains specifically the probe at the miRNA of sequence shown in SEQ ID NO:42-84.
In a kind of optimal way of the present invention, a kind of screening method is provided, described method comprises: the probe of candidate substances with sequence shown in SEQ ID NO:1-10 contacted; Observe the hybridisation events of candidate substances and described probe, wherein, if described candidate substances can with probe hybridization, show that then this candidate substances is the potential material for the treatment of liver cancer.
Preferred, can observe the hybridisation events of candidate substances and described probe by control group is set; Described control group is the system of not adding described candidate substances.
The above-mentioned feature that the present invention mentions, or the feature that embodiment mentions can arbitrary combination.All features that this case specification sheets is disclosed can with any composition forms and usefulness, each feature that is disclosed in the specification sheets can anyly provide the alternative characteristics of identical, impartial or similar purpose to replace.Therefore removing has special instruction, and the feature that is disclosed only is the general example of equalization or similar features.
Major advantage of the present invention is:
1, discloses first and proved that a class micro ribonucleic acid and liver cancer are closely related, found the important biomolecule mark that can be used as the liver cancer clinical diagnosis, for the diagnosis or the control of this disease provides new target spot;
2, disclose the miRNA express spectra of sequence shown in SEQ ID NO:1-84 and first, for the control of relative disease provides effective way with the dependency of liver cancer;
3, the inventor has analyzed the level of micro ribonucleic acid in a large amount of liver cancer patients, and has done careful comparison with the normal people, so the result accurately and reliably.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, people such as Sambrook for example, molecular cloning: laboratory manual (New York:Cold SpringHarbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.Unless otherwise indicated, otherwise all per-cent and umber by weight.
Unless otherwise defined, the same meaning that employed all specialties and scientific words and one skilled in the art are familiar with in the literary composition.In addition, any method similar or impartial to described content and material all can be applicable in the inventive method.The usefulness that preferable implementation method described in the literary composition and material only present a demonstration.
Checking embodiment
Materials and methods
Pathological anatomy:
The 78 pairs of cancers and cancer beside organism come from the excision sample of Patients with Primary, and these samples go from first Pathology Deparment of affiliated hospital of Zhejiang University with start liver cancer research institute.10 routine normal hepatocytes are from unexpected death person.Obtained all tissue samples are the agreement of the Ethics Committee of cooperative association of the World Health Organization by the Shanghai City government authorization all.The excision sample has all passed through pathological analysis, and pathological grading is according to the Edmonson standard.Clinical data comprises: age, sex, tumour size, pathological grading, nodus lymphoideus transferring rate, liver cirrhosis state, HBV and HCV infection conditions, these data all come from patient's case notes.All do not accept chemotherapy before all patient's arts, postoperative is followed up a case by regular visits to and is reached 48 hours most.
The MicroRNA chip:
Probe design is at ripe miRNAs sequence, the miRNAs sequence from the sanger database download (
Http:// microrna.sanger.ac.ukMiRBase Release 7.0, accessed June, 2005). target sequence comprises 435 of human miRNAs, and the sequence of 122 prediction miRNAs sequences and 75 rats and mouse amounts on the chip and comprised that 509 targets are in ripe miRNAs probe.In addition we have designed 8 known RNA does not have complementary bonded oligonucleotide sequence as negative control.Other target miRNAs probe adopts the miRNA Probe Construction Kit (Ambion, Austin, TX USA) of Ambion company synthetic.
RNA extracting and sample are prepared:
The miRNAs extraction agent box extracting with Ambion company of being rich in miRNA obtains, and concrete operations are according to the little RNA of respective description book.The sample method (11) of T4RNA ligase enzyme markers step according to Thomson '.In brief, the little RNA of 4 μ g and 500ng 5 '-phosphoric acid salt-cytosine(Cyt)-uridylic-cy3-3 ' (Dharmacon, Chicago, USA) and the 2 2units T4RNA ligase of unit (NEB, Ipswich USA), were hatched 2 hours in 4 ℃, and miRNA is carried out mark.Every part of miRNA sample is all established the corresponding negative control of equivalent.The RNA of mark precipitates with 0.3M sodium-acetate and 2.5 volume ethanol, contains resuspended, all hybridization repetition twice of hybridization solution of 3 * SSC, 0.2%SDS and 15% methane amide again with 15 μ l, hybridization LifterSlip
TM(Erie, PA USA) evenly flows between chip and cover plate to guarantee hybridization solution.Hybridization chamber is placed on hybridization instrument BioMixer
TMII is last, and (CapitalBio Corp, Beijing China) spend the night in 42 ℃ of water-bath hybridization, wash twice with washing lotion afterwards.
Real-time RT-PCR proofing chip result:
The RNA sample is used
The synthesizing single-stranded cDNA of MicroRNA reverse transcription test kit (Applied Biosystems, Foster, USA).We carry out relative quantitative assay with U43 as confidential reference items with ABI synthetic mi RNA of company and U43MGB probe in detecting PCR product.Each reverse transcription reaction 1-10ng miRNA, target gene and U43 carry out reverse transcription in same reaction system.Relative quantification real-time PCR reaction with ABI 7300 systems react (Applied Biosystems, Foster, USA).This research application looped-primer carries out the reaction of special reverse transcription and guarantees that the goal gene that detects only is ripe miRNAs.
The statistical study of chip data:
The image LuxScan of chip hybridization
TMThe 10K scanner scanning obtains, and passes through LuxScan
TMSoftware is quantitative.The pre-treatment of data comprises: background deduction, and data filter and markization, the numerical value of expression level carries out log and transforms.These processing are all finished with the R software package.Signal hybridization value is higher than 100 microRNA at 1/3rd sample does follow-up analysis.(Multi-dimensional scaiing MDS) analyzes the expression spectral pattern of all miRNAs at all samples with the multiple item scale method.Afterwards we with four kinds of methods (Student ' s t check, the Wilcoxon check, eBayes check and microarray significance analysis (SAM)) analyzed by cancer and the cancer, cancer is with normal, other and the normal difference of cancer, the difference person that all has the statistical significance is defined as differential expression microRNAs. wrong discovery rate in all analyses and is made as less than 0.01 (FDR＜0.01) statistical significance is arranged in three kinds of methods therein.
The result
Different miRNA express spectral pattern and differentiate that liver cancer, cancer take up normal liver tissue
We analyze the express spectra of the miRNA of 78 pairs of liver cancer and cancer beside organism and 10 routine normal hepatocytes with miRNAs oligonucleotide chip (comprising 509 probes).Find that 84 miRNAs expression between liver cancer, cancer side or normal hepatocytes has notable difference.Wherein there are 10 miRNAs to express between the other and per two kinds of tissues of normal liver tissue in liver cancer, cancer that all there were significant differences, see table 1 for details.The above results sees table 1 for details, Fig. 1.With the separating capacity of 69 miRNAs that stay the other difference of a cross validation method analysis love and cancer of SVMs, 89.70% liver cancer and cancer are other can correctly be distinguished afterwards.Therefore this spectral pattern can be used as the diagnosis molecule marker.
The differential expression (p＜0.05) of table 184 miRNA in liver cancer tissue (HCC), cancer beside organism (N) and normal liver tissue (NL)
84 microRNAs notable difference between liver cancer, cancer side and normal liver tissue is expressed, and figure is the non-surveillance authority class results of 84 microRNAs at liver cancer, cancer side and normal liver tissue express spectra.
Described 84 microRNAs and nucleotide sequence thereof are as shown in table 2:
| MiRNA ID | SEQUENCE | SEQ ID NO： |
| hsa-miR-101 | UACAGUACUGUGAUAACUGAAG | SEQ ID NO：1 |
| hsa-miR-148a | UCAGUGCACUACAGAACUUUGU | SEQ ID NO：2 |
| hsa-miR-181a | AACAUUCAACGCUGUCGGUGAGU | SEQ ID NO：3 |
| hsa-miR-214 | ACAGCAGGCACAGACAGGCAG | SEQ ID NO：4 |
| hsa-miR-221 | AGCUACAUUGUCUGCUGGGUUUC | SEQ ID NO：5 |
| hsa-miR-222 | AGCUACAUCUGGCUACUGGGUCUC | SEQ ID NO：6 |
| hsa-miR-25 | CAUUGCACUUGUCUCGGUCUGA | SEQ ID NO：7 |
| hsa-miR-29c | UAGCACCAUUUGAAAUCGGU | SEQ ID NO：8 |
| hsa-miR-34a | UGGCAGUGUCUUAGCUGGUUGUU | SEQ ID NO：9 |
| hsa-miR-424 | CAGCAGCAAUUCAUGUUUUGAA | SEQ ID NO：10 |
| hsa-let-7i | UGAGGUAGUAGUUUGUGCUGU | SEQ ID NO：11 |
| hsa-miR-106b | UAAAGUGCUGACAGUGCAGAU | SEQ ID NO：12 |
| hsa-miR-107 | AGCAGCAUUGUACAGGGCUAUCA | SEQ ID NO：13 |
| hsa-miR-134 | UGUGACUGGUUGACCAGAGGG | SEQ ID NO：14 |
| hsa-miR-155 | UUAAUGCUAAUCGUGAUAGGGG | SEQ ID NO：15 |
| hsa-miR-15b | UAGCAGCACAUCAUGGUUUACA | SEQ ID NO：16 |
| hsa-miR-185 | UGGAGAGAAAGGCAGUUCCUGA | SEQ ID NO：17 |
| hsa-miR-188 | CAUCCCUUGCAUGGUGGAGGGU | SEQ ID NO：18 |
| hsa-miR-18a | UAAGGUGCAUCUAGUGCAGAUA | SEQ ID NO：19 |
| hsa-miR-191 | CAACGGAAUCCCAAAAGCAGCU | SEQ ID NO：20 |
| hsa-miR-202 | AGAGGUAUAGGGCAUGGGAA | SEQ ID NO：21 |
| hsa-miR-210 | CUGUGCGUGUGACAGCGGCUGA | SEQ ID NO：22 |
| hsa-miR-224 | CAAGUCACUAGUGGUUCCGUUUA | SEQ ID NO：23 |
| hsa-miR-29a | UAGCACCAUCUGAAAUCGGUU | SEQ ID NO：24 |
| hsa-miR-30c | UGUAAACAUCCUACACUCUCAGC | SEQ ID NO：25 |
| hsa-miR-30d | UGUAAACAUCCCCGACUGGAAG | SEQ ID NO：26 |
| hsa-miR-331 | GCCCCUGGGCCUAUCCUAGAA | SEQ ID NO：27 |
| hsa-miR-422a | CUGGACUUAGGGUCAGAAGGCC | SEQ ID NO：28 |
| hsa-miR-422b | CUGGACUUGGAGUCAGAAGGCC | SEQ ID NO：29 |
| hsa-miR-451 | AAACCGUUACCAUUACUGAGUUU | SEQ ID NO：30 |
| hsa-miR-520b | AAAGUGCUUCCUUUUAGAGGG | SEQ ID NO：31 |
| hsa-miR-520d | AAAGUGCUUCUCUUUGGUGGGUU | SEQ ID NO：32 |
| hsa-miR-520f | AAGUGCUUCCUUUUAGAGGGUU | SEQ ID NO：33 |
| hsa-miR-92 | UAUUGCACUUGUCCCGGCCUG | SEQ ID NO：34 |
| hsa-miR-93 | AAAGUGCUGUUCGUGCAGGUAG | SEQ ID NO：35 |
| hsa-miR-98 | UGAGGUAGUAAGUUGUAUUGUU | SEQ ID NO：36 |
| PREDICTED_MIR165 | CAGCACCACUUGCAGGGGAGGG | SEQ ID NO：37 |
| PREDICTED_MIR166 | UCGAAGCCUUGGGUGUGGGAGG | SEQ ID NO：38 |
| PREDICTED_MIR189 | UGCUGGUGAGGGAGCCCUGCUG | SEQ ID NO：39 |
| hsa-miR-100 | AACCCGUAGAUCCGAACUUGUG | SEQ ID NO：40 |
| hsa-miR-103 | AGCAGCAUUGUACAGGGCUAUGA | SEQ ID NO：41 |
| hsa-let-7b | UGAGGUAGUAGGUUGUGUGGUU | SEQ ID NO：42 |
| hsa-miR-125a | UCCCUGAGACCCUUUAACCUGUG | SEQ ID NO：43 |
| hsa-miR-146b | UGAGAACUGAAUUCCAUAGGCU | SEQ ID NO：44 |
| hsa-miR-150 | UCUCCCAACCCUUGUACCAGUG | SEQ ID NO：45 |
| hsa-miR-192 | CUGACCUAUGAAUUGACAGCC | SEQ ID NO：46 |
| hsa-miR-19b | UGUGCAAAUCCAUGCAAAACUGA | SEQ ID NO：47 |
| hsa-miR-200b | UAAUACUGCCUGGUAAUGAUGA | SEQ ID NO：48 |
| hsa-miR-215 | AUGACCUAUGAAUUGACAGAC | SEQ ID NO：49 |
| hsa-miR-26b | UUCAAGUAAUUCAGGAUAGGUU | SEQ ID NO：50 |
| hsa-miR-29b | UAGCACCAUUUGAAAUCAGUGUU | SEQ ID NO：51 |
| hsa-miR-342 | UCUCACACAGAAAUCGCACCCGUC | SEQ ID NO：52 |
| PREDICTED_MIR191 | CAACGGAAUCCCAAAAGCAGCU | SEQ ID NO：53 |
| hsa-miR-106a | AAAAGUGCUUACAGUGCAGGUAGC | SEQ ID NO：54 |
| hsa-miR-17-5p | CAAAGUGCUUACAGUGCAGGUAGU | SEQ ID NO：55 |
| hsa-miR-20a | UAAAGUGCUUAUAGUGCAGGUAG | SEQ ID NO：56 |
| hsa-miR-20b | CAAAGUGCUCAUAGUGCAGGUAG | SEQ ID NO：57 |
| hsa-miR-10a | UACCCUGUAGAUCCGAAUUUGUG | SEQ ID NO：58 |
| hsa-miR-122a | UGGAGUGUGACAAUGGUGUUUGU | SEQ ID NO：59 |
| hsa-miR-125b | UCCCUGAGACCCUAACUUGUGA | SEQ ID NO：60 |
| hsa-miR-126 | UCGUACCGUGAGUAAUAAUGCG | SEQ ID NO：61 |
| hsa-miR-130a | CAGUGCAAUGUUAAAAGGGCAU | SEQ ID NO：62 |
| hsa-miR-130b | CAGUGCAAUGAUGAAAGGGCAU | SEQ ID NO：63 |
| hsa-miR-154 | UAGGUUAUCCGUGUUGCCUUCG | SEQ ID NO：64 |
| hsa-miR-148b | UCAGUGCAUCACAGAACUUUGU | SEQ ID NO：65 |
| hsa-miR-194 | UGUAACAGCAACUCCAUGUGGA | SEQ ID NO：66 |
| hsa-miR-195 | UAGCAGCACAGAAAUAUUGGC | SEQ ID NO：67 |
| hsa-miR-199a | CCCAGUGUUCAGACUACCUGUUC | SEQ ID NO：68 |
| hsa-miR-199a* | ACAGUAGUCUGCACAUUGGUUA | SEQ ID NO：69 |
| hsa-miR-22 | AAGCUGCCAGUUGAAGAACUGU | SEQ ID NO：70 |
| hsa-miR-27b | UUCACAGUGGCUAAGUUCUGC | SEQ ID NO：71 |
| hsa-miR-296 | AGGGCCCCCCCUCAAUCCUGU | SEQ ID NO：72 |
| hsa-miR-30e-5p | UGUAAACAUCCUUGACUGGA | SEQ ID NO：73 |
| hsa-miR-423 | AGCUCGGUCUGAGGCCCCUCAG | SEQ ID NO：74 |
| hsa-miR-497 | CAGCAGCACACUGUGGUUUGU | SEQ ID NO：75 |
| hsa-miR-516-3p | UGCUUCCUUUCAGAGGGU | SEQ ID NO：76 |
| hsa-miR-523 | AACGCGCUUCCCUAUAGAGGG | SEQ ID NO：77 |
| hsa-miR-99a | AACCCGUAGAUCCGAUCUUGUG | SEQ ID NO：78 |
| hsa-miR-99b | CACCCGUAGAACCGACCUUGCG | SEQ ID NO：79 |
| PREDICTED_MIR207 | ACUUUGUGCUGGUGCCGGGGAA | SEQ ID NO：80 |
| PREDICTED_MIR240 | UAUUGCCACAACUUUGGGGUGA | SEQ ID NO：81 |
| hsa-let-7f | UGAGGUAGUAGAUUGUAUAGUU | SEQ ID NO：82 |
| hsa-miR-365 | UAAUGCCCCUAAAAAUCCUUAU | SEQ ID NO：83 |
| hsa-miR-24 | UGGCUCAGUUCAGCAGGAACAG | SEQ ID NO：84 |
With real-time RT-PCR method proofing chip result:
We adopt Real-time RT-PCR method proofing chip result.This detection miRNAs detection kit of ABI company, wherein comprise specific reverse transcriptase primer of miRNA and MGB probe, be ripe miRNAs only to guarantee detected purpose product, and do not comprise precursor, the accuracy that detects is very high, and the difference of 1 base can be distinguished.We have selected 8 cancers and the significant miRNAs of the other differential expression of cancer, and each miRNAs analyzes their expressions at 5 pairs of tissues.We are that confidential reference items have carried out relative quantitative assay with U43, result's paired t-test statistical study.Real-time RT-PCR result shows that 6 microRNAs raise in cancer tissues expressed, and 2 down-regulated expressions conform to fully with chip results, and concrete outcome is seen Fig. 2.
The result shows that the chip detecting method accuracy is fine.
The liver cancer susceptibility detection kit
As described in embodiment 1, micro ribonucleic acid and liver cancer shown in sequence SEQ ID NO:1-84 are closely related.Therefore, can detect based on this extracting patient's miRNA.
Prepare a test kit (100 person-times), it contains the miRNA chip, is fixed with on the chip specifically at the probe of micro ribonucleic acid, and described micro ribonucleic acid is respectively shown in sequence SEQ ID NO:1-84.
Whether the test group that 100 people of random choose constitute is suffered from the patient of the object of liver cancer, known trouble liver cancer and is not had the normal people of liver cancer after testing comprising the unknown.
Obtain the hepatic tissue of object to be detected in the test group, use method extracting RNA and preparation test sample, and, obtain express spectra with the chip hybridization in the liver cancer detection kit as embodiment 1.
Detected result:
, further detect to confirm whether to suffer from liver cancer with the close object among the embodiment 1 for express spectra by ordinary method.
Detected result shows, express spectra is with the liver cancer susceptibility ratio of the detected object of the close degree among the embodiment 1 high more (concordance rate 〉=90%) crowd apparently higher than close degree low (concordance rate＜70%).
Therefore, this shows by chip provided by the invention and test kit, can carry out the complementary detection of liver cancer.
The complementary detection of liver cancer susceptibility
Repeat the detection of embodiment 2, difference be picked at random 70 people (not knowing before the detection whether the liver cancer symptom is arranged) detect.
Prepare a test kit (100 person-times), it contains the miRNA chip, is fixed with on the chip specifically at the probe of micro ribonucleic acid, and described micro ribonucleic acid is respectively shown in sequence SEQ ID NO:1-84.
Obtain the hepatic tissue of object to be detected in the test group, use method extracting RNA and preparation test sample, and, obtain express spectra with the chip hybridization in the liver cancer detection kit as embodiment 1.
The result confirmed equally, and express spectra is with the liver cancer susceptibility ratio of the detected object of the close degree among the embodiment 1 high more (concordance rate 〉=90%) crowd apparently higher than close degree low (concordance rate＜70%).
Based on SVMs and the prediction of staying a cross validation method
Find with embodiment 1 described method, in 84 microRNAs, the expression level significant difference of 69 microRNAs in liver cancer and the other hepatic tissue of cancer (HCC vs.N) arranged, and then the contriver makes up SVMs (SVM, support vector machine) predictive model is used the accuracy of staying a cross validation method (leave-one-outcross-val idation prediction models) to be woven to liver cancer or the other hepatic tissue of cancer according to the express spectra prediction group of 69 differential expression microRNAs.
The result shows that 89.70% liver cancer and the other hepatic tissue of cancer can correctly be distinguished.Between other liver of cancer and healthy tissues, there are 27 microRNAs to express significant difference and express.With SVMs with stay an interior extrapolation analysis, result to show that other liver of 97.7% cancer and healthy tissues can correctly be distinguished.Between liver cancer and healthy tissues, there are 55 microRNAs to there are differences expression.With SVMs and stay a cross validation model, result to show that 100% liver cancer and healthy tissues can correctly be distinguished.
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Sequence table
＜110〉Shanghai Inst. of Tumor
＜120〉a kind of gene chip and application thereof
<130>080198
<160>84
<170>PatentIn version 3.3
<210>1
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>1
uacaguacug ugauaacuga ag 22
<210>2
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>2
<210>3
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>3
aacauucaac gcugucggug agu 23
<210>4
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>4
acagcaggca cagacaggca g 21
<210>5
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>5
agcuacauug ucugcugggu uuc 23
<210>6
<211>24
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>6
agcuacaucu ggcuacuggg ucuc 24
<210>7
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>7
cauugcacuu gucucggucu ga 22
<210>8
<211>20
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>8
uagcaccauu ugaaaucggu 20
<210>9
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>9
uggcaguguc uuagcugguu guu 23
<210>10
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>10
cagcagcaau ucauguuuug aa 22
<210>11
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>11
ugagguagua guuugugcug u 21
<210>12
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>12
uaaagugcug acagugcaga u 21
<210>13
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>13
agcagcauug uacagggcua uca 23
<210>14
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>14
ugugacuggu ugaccagagg g 21
<210>15
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>15
uuaaugcuaa ucgugauagg gg 22
<210>16
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>16
uagcagcaca ucaugguuua ca 22
<210>17
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>17
uggagagaaa ggcaguuccu ga 22
<210>18
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>18
caucccuugc augguggagg gu 22
<210>19
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>19
<210>20
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>20
caacggaauc ccaaaagcag cu 22
<210>21
<211>20
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>21
agagguauag ggcaugggaa 20
<210>22
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>22
cugugcgugu gacagcggcu ga 22
<210>23
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>23
caagucacua gugguuccgu uua 23
<210>24
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>24
uagcaccauc ugaaaucggu u 21
<210>25
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>25
uguaaacauc cuacacucuc agc 23
<210>26
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>26
uguaaacauc cccgacugga ag 22
<210>27
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>27
gccccugggc cuauccuaga a 21
<210>28
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>28
cuggacuuag ggucagaagg cc 22
<210>29
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>29
cuggacuugg agucagaagg cc 22
<210>30
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>30
aaaccguuac cauuacugag uuu 23
<210>31
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>31
aaagugcuuc cuuuuagagg g 21
<210>32
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>32
aaagugcuuc ucuuuggugg guu 23
<210>33
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>33
aagugcuucc uuuuagaggg uu 22
<210>34
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>34
uauugcacuu gucccggccu g 21
<210>35
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>35
aaagugcugu ucgugcaggu ag 22
<210>36
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>36
ugagguagua aguuguauug uu 22
<210>37
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>37
cagcaccacu ugcaggggag gg 22
<210>38
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>38
ucgaagccuu ggguguggga gg 22
<210>39
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>39
ugcuggugag ggagcccugc ug 22
<210>40
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>40
aacccguaga uccgaacuug ug 22
<210>41
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>41
agcagcauug uacagggcua uga 23
<210>42
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>42
ugagguagua gguugugugg uu 22
<210>43
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>43
ucccugagac ccuuuaaccu gug 23
<210>44
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>44
<210>45
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>45
ucucccaacc cuuguaccag ug 22
<210>46
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>46
cugaccuaug aauugacagc c 21
<210>47
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>47
ugugcaaauc caugcaaaac uga 23
<210>48
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>48
uaauacugcc ugguaaugau ga 22
<210>49
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>49
augaccuaug aauugacaga c 21
<210>50
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>50
uucaaguaau ucaggauagg uu 22
<210>51
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>51
uagcaccauu ugaaaucagu guu 23
<210>52
<211>24
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>52
ucucacacag aaaucgcacc cguc 24
<210>53
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>53
caacggaauc ccaaaagcag cu 22
<210>54
<211>24
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>54
aaaagugcuu acagugcagg uagc 24
<210>55
<211>24
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>55
caaagugcuu acagugcagg uagu 24
<210>56
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>56
uaaagugcuu auagugcagg uag 23
<210>57
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>57
caaagugcuc auagugcagg uag 23
<210>58
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>58
uacccuguag auccgaauuu gug 23
<210>59
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>59
uggaguguga caaugguguu ugu 23
<210>60
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>60
ucccugagac ccuaacuugu ga 22
<210>61
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>61
ucguaccgug aguaauaaug cg 22
<210>62
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>62
cagugcaaug uuaaaagggc au 22
<210>63
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>63
cagugcaaug augaaagggc au 22
<210>64
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>64
<210>65
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>65
<210>66
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>66
uguaacagca acuccaugug ga 22
<210>67
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>67
uagcagcaca gaaauauugg c 21
<210>68
<211>23
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>68
cccaguguuc agacuaccug uuc 23
<210>69
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>69
<210>70
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>70
<210>71
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>71
uucacagugg cuaaguucug c 21
<210>72
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>72
agggcccccc cucaauccug u 21
<210>73
<211>20
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>73
uguaaacauc cuugacugga 20
<210>74
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>74
agcucggucu gaggccccuc ag 22
<210>75
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>75
cagcagcaca cugugguuug u 21
<210>76
<211>18
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>76
ugcuuccuuu cagagggu 18
<210>77
<211>21
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>77
aacgcgcuuc ccuauagagg g 21
<210>78
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>78
aacccguaga uccgaucuug ug 22
<210>79
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>79
<210>80
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>80
acuuugugcu ggugccgggg aa 22
<210>81
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>81
uauugccaca acuuuggggu ga 22
<210>82
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>82
ugagguagua gauuguauag uu 22
<210>83
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>83
uaaugccccu aaaaauccuu au 22
<210>84
<211>22
<212>RNA
＜213〉homo sapiens (Homo sapiens)
<400>84
uggcucaguu cagcaggaac ag 22
Claims (10)
1. a chip is characterized in that, it contains specifically at the probe of micro ribonucleic acid, and the sequence of described micro ribonucleic acid is shown in SEQ ID NO:1-10.
2. chip as claimed in claim 1 is characterized in that, it also contains specifically the probe at the micro ribonucleic acid of one or more sequences shown in SEQ IDNO:11-41; Preferably, it also contains specifically the probe at the micro ribonucleic acid of one or more sequences shown in SEQ IDNO:42-84.
3. a test kit is characterized in that, described test kit comprises:
One container;
Be arranged in described container specifically at the probe of micro ribonucleic acid, the sequence of described micro ribonucleic acid is shown in SEQ IDNO:1-10; And
Specification sheets;
And every kind of probe links to each other with detectable mark, and the detected mark that links to each other on the different probe is also different; Preferably, described mark is fluorescent microsphere, indole cyanine dyes.
4. test kit as claimed in claim 3 is characterized in that, also contains specifically the probe at the micro ribonucleic acid of one or more sequences shown in SEQ ID NO:11-41 in the described test kit; Preferably, also contain specifically probe in the described test kit at the micro ribonucleic acid of one or more sequences shown in SEQ ID NO:42-84.
5. a test kit that is used to detect liver cancer is characterized in that, it contains chip as claimed in claim 1 and specification sheets.
6. the purposes of chip according to claim 1 is characterized in that described chip is used to prepare the test kit of differentiating liver cancer tissue, cancer beside organism and/or healthy tissues.
7. the purposes of a micro ribonucleic acid, wherein said micro ribonucleic acid comprises the oligonucleotide of sequence shown in SEQ ID NO:1-10, it is characterized in that, is used for reagent or test kit that liver cancer tissue, cancer beside organism and/or healthy tissues are differentiated in preparation (a); Or (b) detect the reagent or the test kit of liver cancer; Preferably described reagent is specifically at the probe of micro ribonucleic acid.
8. the method for the medium and small ribonucleotide of external non-diagnostic assays nucleic acid samples is characterized in that described method comprises step:
(i) nucleic acid samples is contacted with the probe at micro ribonucleic acid specifically, the sequence of described micro ribonucleic acid is shown in SEQID NO:1-10;
(ii) per sample with the hybridisation events of the probe of micro ribonucleic acid, obtain the express spectra of described micro ribonucleic acid;
Preferably, described probe is positioned on the chip; More preferably, described nucleic acid samples is an extracting nucleic acid.
9. a method that detects liver cancer is characterized in that, described method comprises step:
(i) system to be checked is contacted with the probe that contains specifically at micro ribonucleic acid, the sequence of described micro ribonucleic acid is shown in SEQ ID NO:1-10;
(ii) observe the hybridisation events of system to be checked and described probe, wherein, if described system to be checked can with probe hybridization, show that then there is the possibility of liver cancer in this system to be checked;
Described system to be checked is selected tissue, cell system or extractive nucleic acid.
10. the method for a screening of candidate substances is characterized in that, described method comprises step:
(a) will wait to screen material contacts with the liver cancer cell culture of experimental group, detect micro ribonucleic acid in the described liver cancer cell then, the sequence of wherein said micro ribonucleic acid is shown in SEQ ID NO:1-10, thus the express spectra of little ribonucleotide described in the acquisition experimental group liver cancer cell;
(b) express spectra with little ribonucleotide described in the express spectra of little ribonucleotide described in the experimental group liver cancer cell and blank group express spectra and the normal liver cell compares, and described blank group express spectra is a liver cancer cell culture of waiting to screen material from not adding;
Wherein, if concordance rate＜70% of experimental group express spectra and blank group express spectra illustrates that this material to be screened is the potential material relevant with the small nut sugar nucleotide express spectra of liver cancer, can be used as the basis of further screening; Preferably, concordance rate＜50%, more preferably, concordance rate＜20%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100358406A CN101555519A (en) | 2008-04-10 | 2008-04-10 | Gene chip and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100358406A CN101555519A (en) | 2008-04-10 | 2008-04-10 | Gene chip and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101555519A true CN101555519A (en) | 2009-10-14 |
Family
ID=41173798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100358406A Pending CN101555519A (en) | 2008-04-10 | 2008-04-10 | Gene chip and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101555519A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804208A (en) * | 2010-02-26 | 2010-08-18 | 南京医科大学 | Application of miR-451 in preparing medicine for treating non-small cell lung cancer |
| CN102140467A (en) * | 2010-12-30 | 2011-08-03 | 苏州吉玛基因股份有限公司 | Human miR-365 antisense nucleic acid and application thereof |
| CN103397033A (en) * | 2013-08-13 | 2013-11-20 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Separated oligonucleotide rno-miR-181a and application thereof in brain mitochondria damage |
| CN104147616A (en) * | 2014-08-06 | 2014-11-19 | 清华大学深圳研究生院 | Application of dsRNA or modification thereof in preparation of tumor inhibitor |
| CN104372087A (en) * | 2014-11-06 | 2015-02-25 | 中山大学 | Liver cancer diagnosis markers composed of serum microRNA (microribonucleic acid) and diagnosis kit |
| CN106709267A (en) * | 2017-01-25 | 2017-05-24 | 武汉贝纳科技服务有限公司 | Data acquisition method and device |
| CN111449025A (en) * | 2020-04-02 | 2020-07-28 | 华北理工大学 | Application of miRNAs in inhibition of rat hepatic fibrosis |
-
2008
- 2008-04-10 CN CNA2008100358406A patent/CN101555519A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804208A (en) * | 2010-02-26 | 2010-08-18 | 南京医科大学 | Application of miR-451 in preparing medicine for treating non-small cell lung cancer |
| CN102140467A (en) * | 2010-12-30 | 2011-08-03 | 苏州吉玛基因股份有限公司 | Human miR-365 antisense nucleic acid and application thereof |
| CN102140467B (en) * | 2010-12-30 | 2013-05-15 | 苏州吉玛基因股份有限公司 | Human miR-365 antisense nucleic acid and application thereof |
| CN103397033A (en) * | 2013-08-13 | 2013-11-20 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Separated oligonucleotide rno-miR-181a and application thereof in brain mitochondria damage |
| CN103397033B (en) * | 2013-08-13 | 2015-07-08 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Separated oligonucleotide rno-miR-181a and application thereof in brain mitochondria damage |
| CN104147616A (en) * | 2014-08-06 | 2014-11-19 | 清华大学深圳研究生院 | Application of dsRNA or modification thereof in preparation of tumor inhibitor |
| CN104372087A (en) * | 2014-11-06 | 2015-02-25 | 中山大学 | Liver cancer diagnosis markers composed of serum microRNA (microribonucleic acid) and diagnosis kit |
| CN104372087B (en) * | 2014-11-06 | 2016-08-31 | 中山大学 | The diagnosing cancer of liver mark being made up of serum microRNA and diagnostic kit |
| CN106709267A (en) * | 2017-01-25 | 2017-05-24 | 武汉贝纳科技服务有限公司 | Data acquisition method and device |
| CN111449025A (en) * | 2020-04-02 | 2020-07-28 | 华北理工大学 | Application of miRNAs in inhibition of rat hepatic fibrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2438187B1 (en) | Mirna fingerprint in the diagnosis of multiple sclerosis | |
| CN103930563B (en) | For the method and apparatus predicting cancer return | |
| EP2733219B1 (en) | Diagnostic miRNA markers for Alzheimer | |
| KR101912731B1 (en) | Plasma MicroRNAs for The Detection of Early Colorectal Cancer | |
| EP1777301B1 (en) | Analysis of microRNA | |
| US20080076674A1 (en) | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer | |
| Guglielmelli et al. | MicroRNA expression profile in granulocytes from primary myelofibrosis patients | |
| US20070065844A1 (en) | Solution-based methods for RNA expression profiling | |
| US20100286044A1 (en) | Detection of tissue origin of cancer | |
| US11136628B2 (en) | Biomarkers useful for detection of types, grades and stages of human breast cancer | |
| US20140287413A1 (en) | METHODS, COMPOSITIONS, AND DEVICES UTILIZING MicroRNA TO DETERMINE PHYSIOLOGICAL CONDITIONS | |
| US20120219958A1 (en) | MicroRNA Signatures Differentiating Uterine and Ovarian Papillary Serous Tumors | |
| US20110107440A1 (en) | Skin cancer associated micrornas | |
| EP4105338A1 (en) | Detection of nucleic acids | |
| US20120302626A1 (en) | Microrna and use thereof in identification of b cell malignancies | |
| US20130065778A1 (en) | MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy | |
| CN101555519A (en) | Gene chip and application thereof | |
| CA2859021A1 (en) | Methods and kits for detecting subjects at risk of having cancer | |
| US20210002698A1 (en) | miRNA Receptivity Analysis of the Endometrium | |
| WO2014114802A1 (en) | Non-invasive prenatal genetic diagnostic methods | |
| CN101298630A (en) | Method for identifying miRNA in blood serum of colon cancer patient by Solexa technology | |
| CN101555518A (en) | Micro ribonucleic acid and application thereof | |
| Mohammed et al. | miRNAs dysregulation in ankylosing spondylitis: A review of implications for disease mechanisms, and diagnostic markers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20091014 |